We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookiesAcceptRead more

Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • Stock information
    • Governance
    • Documentation

Corporate

19 January 2021

GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

18 January 2021

GenSight Biologics Announces its 2021 Financial Calendar

11 Jan 2021 - 14 Jan 2021

39th Annual J.P. Morgan Healthcare Conference – Virtual

10 December 2020

GenSight Biologics announces the partial conversion of convertible bonds and full exercise of share warrants by Kreos Capital

16 Nov 2020 - 17 Nov 2020

Bryan Garnier European Healthcare Conference 2020 – virtual event

03 November 2020

GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

06 Nov 2020

Eyecelerator 2020 – Virtual Conference

22 October 2020

GenSight Biologics successfully raises €25 million in an oversubscribed private placement with US and European institutional investors

21 October 2020

GenSight Biologics launches a capital increase of approximately €25 million by means of an accelerated bookbuilding process

26 Oct 2020 - 29 Oct 2020

BioEurope – Digital

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 9
  • View next 9 articles
© 2021 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
Go back to the page of the page